Literature DB >> 9576439

Renal and urologic complications of inflammatory bowel disease.

D S Pardi1, W J Tremaine, W J Sandborn, J T McCarthy.   

Abstract

Renal and urologic complications are not uncommon in patients with inflammatory bowel disease, and can be directly or indirectly related to the underlying disease process or its treatment. Many of these patients have asymptomatic disease, or the urinary symptoms are nonspecific or overshadowed by bowel symptoms. By the time a urinary complication is considered, significant disease progression or renal damage may have occurred. These risks necessitate a high degree of diligence and periodic urologic evaluation as part of the long-term management of patients with inflammatory bowel disease.

Entities:  

Mesh:

Year:  1998        PMID: 9576439     DOI: 10.1111/j.1572-0241.1998.156_b.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  43 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

2.  An unusual case of genitourinary complication in ulcerative colitis.

Authors:  Melinda O Amosu; Hayat M Mousa
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

Review 3.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

Review 4.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 5.  Tubulointerstitial nephritis: diagnosis, treatment, and monitoring.

Authors:  Emily Joyce; Paulina Glasner; Sarangarajan Ranganathan; Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2016-05-07       Impact factor: 3.714

6.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Authors:  R A J Ransford; M J S Langman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

7.  Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria.

Authors:  Ruhul Amin; John Asplin; Daniel Jung; Mohamed Bashir; Altayeb Alshaikh; Sireesha Ratakonda; Sapna Sharma; Sohee Jeon; Ignacio Granja; Dietrich Matern; Hatim Hassan
Journal:  Kidney Int       Date:  2018-02-01       Impact factor: 10.612

8.  Use of sevelamer hydrochloride as an oxalate binder.

Authors:  John C Lieske; Cynthia Regnier; John J Dillon
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

9.  Netrin-1 regulates colon-kidney cross talk through suppression of IL-6 function in a mouse model of DSS-colitis.

Authors:  Punithavathi Ranganathan; Calpurnia Jayakumar; Manicassamy Santhakumar; Ganesan Ramesh
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-27

10.  Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study.

Authors:  Laszlo Lakatos; Tunde Pandur; Gyula David; Zsuzsanna Balogh; Pal Kuronya; Arpad Tollas; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.